Introduction {#S1}
============

Pulmonary arterial hypertension (PAH) is characterized by anomalies in pulmonary arteries (abnormal proliferation of smooth muscle and endothelial cells) which results in cardiovascular anomalies such as increase in pulmonary vascular resistance (PVR) and finally right ventricular failure ([@B21]; [@B30]; [@B66]). PAH may present with non-specific symptoms and signs such as generalized fatigue, limitation of daily-activities and dyspnea, and this may prevent clinicians from diagnosing it early in the course of PAH and thus most of the time the diagnosis is made at the time of advanced right heart failure. Right-heart catheterization (RHC) is fundamental to confirm the diagnosis of PAH ([@B66]) and recently a new hemodynamic definition of PAH has been proposed (a mean pulmonary artery pressure \>20 mmHg instead of previous one ≥25 mmHg) based on the analysis of large databases ([@B34]) and a meta-analysis of normal hemodynamics ([@B33]) in order to identify patients with early pulmonary vascular disease ([@B66]).

Cardiopulmonary exercise testing (CPET) is of great interest and utility for clinicians dealing PH in evaluating exercise intolerance and its underpinning mechanisms, accurately assessing exertional dyspnea and unmasking its underlying mechanisms, which are often not straightforward. Previous studies have shown that PAH management at an early stage of the disease translates into better outcomes ([@B22]; [@B31]; [@B35]). Therefore, it appears crucial to establish early diagnosis and CPET can help clinicians in the differential diagnosis and evaluating prognosis in such an especially fragile population.

Pathophysiologic Response-Profile to Exercise in Pulmonary Hypertension {#S2}
=======================================================================

CPET can magnify the PH-related pathophysiologic anomalies and has a major role in the management of PH patients. Pathophysiologic anomalies in PH can widely range from reduced cardiac output and aerobic capacity, to pulmonary gas exchange and ventilatory efficiency anomalies, dyspnea, dynamic hyperinflation and locomotor muscle dysfunction ([Figure 1](#F1){ref-type="fig"}).

![Schematic pathophysiologic pathway leading to exercise intolerance and exertional dyspnea in pulmonary hypertension. RV, right ventricle; LV, left ventricle; V'~E~, minute ventilation; V'~E~/V'CO~2~, ratio of minute ventilation to carbon dioxide production; P~ET~CO~2~, end-tidal pressure of carbon dioxide; V~D~/V~T~, dead space to tidal volume fraction; V'O~2~, oxygen consumption; WR, work rate; O~2~ pulse, V'O~2~ to heart rate (HR) ratio; V'CO~2~, carbon dioxide production; PvO~2~, venous pressure of oxygen; PaO~2~, arterial partial pressure of oxygen; PaCO~2~, arterial partial pressure of carbon dioxide. This is an original figure, no permission is required.](fphys-11-00964-g001){#F1}

Pulmonary vascular obstruction along with concurrent increased mean PAP and PVR and reduced pulmonary capillary bed and recruitment give rise to three different pathophysiologic anomalies: (1) ventilation/perfusion (V/Q) inequalities; (2) pulmonary gas exchange anomalies; (3) increased right ventricle (RV) afterload and concomitant reduced left ventricle (LV) filling. These three major pathophysiologic derangements are responsible of characteristic anomalies observed during CPET that can ultimately explain exertional dyspnea and exercise intolerance ([Figure 1](#F1){ref-type="fig"}).

V/Q inequalities can manifest with either low V/Q ratios and shunt (right to left shunt through a patent foramen ovale, for example) or high V/Q ratios caused by increased minute ventilation (V'~E~) of poorly perfused air spaces ([@B53]) V/Q mismatching can result in hypoxemia (reduced arterial partial pressure of oxygen, PaO~2~), high dead space to tidal volume fraction (V~D~/V~T~) and widening of the alveolar-arterial pressure difference of oxygen \[P(A-a)O~2~\] and of the arterial-end-tidal pressure difference of carbon dioxide \[P(a-ET)CO~2~\]. These anomalies can stimulate an excessive V'~E~ response to exercise along with altered chemosensitivity and inefficient ventilation mirrored by the increased steepness with which V'~E~ rises with respect to CO~2~ production (V'CO~2~) (i.e., increased V'~E~/V'CO~2~ slope) ([@B11]; [@B62]; [@B4]; [@B73]; [@B51]; [@B81]; [@B38]; [@B20]; [@B78]). Inefficient ventilation and altered chemosensitivity translate into increase ventilatory demand, V'~E~/V'CO~2~ and V~D~/V~T~, decrease end-tidal pressure of carbon dioxide (P~ET~CO~2~) and hypocapnia (reduced arterial partial pressure of carbon dioxide, PaCO~2~) ([@B62]; [@B84]; [@B85]; [@B64]; [@B23]; [@B78]).

The reduced pulmonary capillary bed and recruitment at rest can be amplified during CPET and translated in pulmonary gas exchange anomalies such as a relative low alveolar-capillary diffusing capacity; this can be mirrored by a reduced diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO or TLCO) at rest and a reduced PaO~2~ with enlargement of P(A-a)O~2~ during CPET.

Impaired cardiac function (due to increased RV afterload and concomitant reduced LV filling) along with peripheral muscle dysfunction and deconditioning ([@B8]; [@B71]; [@B47]; [@B14]) result in reduced cardiac output and blood flow to the periphery. This translates to reduced oxygen delivery to working locomotor muscles and reduced venous pressure of oxygen (PvO~2~), which results in reduced aerobic capacity with attendant reduced anaerobic threshold (AT) and oxygen consumption (V'O~2~). Reduced oxygen delivery also causes early onset of lactic acidosis and increased V'CO~2~, which further contributes to the excessive V'~E~ response to CPET ([@B52]; [@B70]; [@B12]; [@B27]; [@B50]; [@B75]). The reduced mixed venous O~2~ content from altered cardiac output can also contribute and amplify exertional hypoxemia.

Mechanical anomalies on tidal volume (V~T~) expansion and dynamic lung hyperinflation can also play a crucial role into the genesis of exertional dyspnea and therefore exercise intolerance ([@B61]; [@B38], [@B40]; [@B48]; [@B10]), and can be easily detected during CPET ([@B38], [@B40]; [@B10]).

Peripheral Muscle Dysfunction {#S3}
=============================

Deconditioning and peripheral muscle abnormalities are important contributors to exercise intolerance. In chronic heart failure, which shares similar limitations in cardiac output reserve as PAH and CTEPH, oxygen transport and diffusion at the level of skeletal muscle are abnormal ([@B18]). Tissue oxygen saturation, oxygen extraction and muscle microcirculatory function may be impaired to an even greater degree in PAH compared with left heart failure ([@B71]; [@B14]). Peripheral muscle in PAH patients is structurally and functionally abnormal, with a lower relative proportion of type I fibers and reduced quadriceps, forearm, and respiratory muscle strength compared to controls, which may be an important determinant of low peak V'O~2~ ([@B8]; [@B47]).

Respiratory muscle strength has also been shown to be about 40% lower in CTEPH patients ([@B48]). The mechanism of generalized skeletal muscle dysfunction in PAH may be a result of microcirculation rarefaction and an imbalance in angiogenic factors ([@B56]). Improvements in exercise capacity with exercise training in individuals with heart failure or peripheral vascular disease ([@B16]) have been linked to improvements in skeletal muscle microcirculatory density, capillary-to-fiber ratio and mitochondrial volume ([@B19]), which may be mechanisms by which training can improve exercise capacity in stable patients with PAH ([@B49]; [@B17]). Peripheral muscle dysfunction is a potential relevant e hidden factor that can worsen the prognosis of PAH patients. Recently, Valli et al. have pointed out that patients with PAH may present with less efficient muscular oxygen utilization than healthy controls. Notably high energy expenditure had a relevant independent prognostic impact ([@B72]).

Translating PH-Related Pathophysiologic Anomalies Into CPET Variables: Exploring Factors Explaining Exercise Limitation in PH {#S4}
=============================================================================================================================

One of the indications of CPET is to explore the underlying mechanisms of exertional dyspnea and to detect mechanisms of exercise intolerance. [Table 1](#T1){ref-type="table"} summarizes the main CPET-derived variables defining ventilatory, respiratory mechanical, cardiovascular and pulmonary vascular limitation accompanied or not by gas exchange anomalies to exercise.

###### 

Variables defining ventilatory and respiratory mechanical limitation (left panel) accompanied or not by gas exchange anomalies to exercise, and variables defining cardiovascular and pulmonary vascular limitation (right panel) accompanied or not by gas exchange anomalies to exercise.

  **Ventilatory and respiratory mechanical limitation to exercise**                       **Cardiovascular and pulmonary vascular limitation to exercise**
  --------------------------------------------------------------------------------------- ------------------------------------------------------------------
  BR \< 15--20%                                                                           BR \> 15--20%
  Dynamic Hyperinflation (decrease in IC \> 140 mL)                                       V'O~2~/HR \< 70%
  V~T~ plateau                                                                            V'O~2~/Work Rate↓
  RR \> 50--55 breaths/min (if restrictive pattern)                                       Flat (and declining) V'O2/HR trajectory
  V~T~ = IC or \> 60% VC (if restrictive pattern)                                         Abnormal HR/V'O~2~ slope (\>50)
  HR peak \< HR predicted                                                                 Chronotropic incompetence
  EILV \>90% TLC at peak exercise                                                         Abnormal blood pressure response to exercise
  V~T~/IC \>70% at peak exercise                                                          ECG abnormalities during exercise
  The tidal inspiratory flow \>50 to 70% maximal inspiratory flow (in health \<50--70%)   
  **With or without**                                                                     **With or without**
  Gas exchange anomalies:                                                                 Gas exchange anomalies:
   V~D~/V~T~ ↑                                                                             V~D~/V~T~ ↑
   P(A-a)O~2~ ↑                                                                            P(A-a)O~2~ ↑
   Decrease of PaO~2~ ≥ 10 mmHg                                                            Decrease of PaO~2~ ≥ 10 mmHg
   Decrease of SpO~2~ ≥ 5% and/or SpO~2~ peak ≤ 88%                                        Decrease of SpO~2~ ≥ 5% and/or SpO~2~ peak ≤ 88%
   PaCO~2~ peak \> 45--50 mmHg                                                            

BR, breathing reserve; IC, Inspiratory Capacity; VT, tidal volume; RR, Respiratory Rate; VC, Vital Capacity; HR, Heart Rate; EILV, End-Inspiratory Lung Volume; VD/VT, dead space to tidal volume fraction; P(A-a)O

2

, alveolar-arterial pressure difference of oxygen;, PaO

2

, partial pressure of oxygen; SpO

2

, pulse oximetry saturation; PaCO

2

, arterial partial pressure of carbon dioxide; V'O

2

, oxygen consumption; P(a-ET)CO

2

, arterial-end-tidal pressure difference of carbon dioxide; ↓, reduced; ↑, increased.

Two variables are used to detect exercise intolerance ([@B59]) peak V'O~2~ during an incremental CPET has well defined normal values ([@B57]) and V'O~2~ at the anaerobic/ventilatory threshold (AT) has the advantage of being an effort independent measure of exercise tolerance ([@B3]; [@B5]; [@B54]; [@B58]; [@B29]). The disadvantage is that it relies on pattern recognition for accurate detection (which may differ from operator to operator due to lack of experience or inaccurate detection related to software - never trust software for detecting AT! - or wrong pattern recognition) and some severely impaired PH patients may not be able to attain the AT despite a good effort.

Cardiovascular limitation to exercise is not straightforward and may be defined by certain interrelated variables ([Table 1](#T1){ref-type="table"}). A reduced slope or late plateau of the V'O~2~ trajectory (i.e., a reduced V'O~2~/work rate relationship ≤8), or plateau (early or late during exercise) of the oxygen pulse (V'O~2~ to heart rate ratio, i.e., V'O~2~/HR), or an abnormal HR/V'O~2~ slope (\>50) may be typical ([@B55]).

Pulmonary vascular limitation to exercise is not straightforward as well and may rely on evidence of increased V'~E~/V'CO~2~ slope and ratio at AT in addition to the above-mentioned anomalies ([@B76]). Other typical features of pulmonary vascular disease are low levels of P~ET~CO~2~ at AT, a V~D~/V~T~ which remains stable or increases or fails to decrease from baseline, a P(a-ET)CO~2~ which fails to became negative during exercise and, sometimes, a P(A-a)O~2~ which widens on exertion ([@B78]; [Table 1](#T1){ref-type="table"}). Of note, it should be pointed out that the finding of high V'~E~/V'CO~2~ at AT (≥34--35) and low P~ET~CO~2~ at AT (≤30 mmHg) without an alternative explanation in patients presenting with unexplained dyspnea and exercise limitation should prompt further diagnostic testing to exclude PAH or CTEPH ([@B76]) particularly in those patients with risk factors, such as prior venous thromboembolism, systemic sclerosis or a family history of PAH. These gas exchange anomalies are usually not found in patients with pulmonary venous hypertension secondary to cardiac diseases ([@B76]). Associated low level of hemoglobin will enhance oxygen flow deficiency. Ischemic heart disease or cardiomyopathy may present with electrocardiographic or blood pressure anomalies during CPET ([@B55]).

Pulmonary gas exchange limitation to exercise is not straightforward as well and may rely on evidence of inefficient carbon dioxide exchange which can be signaled by high V~D~/V~T~ and often by high exercise V'~E~/V'CO~2~ ([Figure 2](#F2){ref-type="fig"}) or (alone or in combination with) inadequate oxygen exchange signaled by low PaO~2~ or, less directly, by desaturation at pulse oximetry.

![Examples of ventilatory efficiency (V'~E~/V'CO~2~ slope) in a healthy subject with a peak oxygen uptake (V'O~2~) of 38 mL/Kg/min (black line and rhomboid), in a patient with pulmonary veno-occlusive disease (PVOD) with a peak V'O~2~ of 18 mL/Kg/min (violet line and circles), in a patient with pulmonary arterial hypertension (PAH) with a peak V'O~2~ of 18 mL/Kg/min (red line and triangles) and in a patient with chronic thromboembolic pulmonary hypertension (CTEPH) with a peak V'O~2~ of 18 mL/Kg/min (blue line and squares). This is an original figure, no permission is required.](fphys-11-00964-g002){#F2}

Elevated V'~E~/V'CO~2~ (ventilatory inefficiency) and reduced resting PaCO~2~ (hypocapnia) are frequent in pulmonary vascular disease such as PAH, chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary veno-occlusive disease (PVOD) ([@B76]) and correlate with negative prognosis ([@B28]; [@B13]; [@B65]; [@B25]). Abnormally reduced resting PaCO~2~ signals augmented chemosensitivity or an abnormal PaCO~2~ set-point. A low resting PaCO~2~ predicts a worse prognosis in PAH ([@B28]). However, high V~D~/V~T~ does not cause low resting PaCO~2~, therefore an altered PaCO~2~ set-point, increased neural respiratory drive, and/or increased chemosensitivity must explain hypocapnia and consequently, the high V'~E~/V'CO~2~ slope. Several factors such as metabolic acidosis, hypoxemia, baroreceptors in the pulmonary vessels and abnormal activation of the sympathetic nervous system have an influence on the PaCO~2~ set-point ([@B74]; [@B83]; [@B69]; [@B73]; [@B80]; [@B38]; [@B77]). The evaluation of chemosensitivity and/or the PaCO~2~ set-point during exercise is difficult and can be problematic. Autonomic dysfunction, increased sympathetic nervous system activity, and an altered CO~2~ set-point relate to chemoreflex sensitivity. Recently [@B20] performed minute-to-minute blood gas analysis during exercise in 18 patients with pulmonary vascular disease. They run hypoxic and hypercapnic challenge tests to assess peripheral and central chemosensitivity and found an increase in chemoreceptor sensitivity in both PAH and CTEPH that did not correlate (the peripheral chemoreceptor responses to hypoxia and hypercapnia) with any exercise variables. The "non-invasive" evaluation of the PaCO~2~ set-point during exercise is extremely difficult; one method is to assess the maximal end-tidal CO~2~ pressure (maximal P~ET~CO~2~) value between the AT and respiratory compensation point where P~ET~CO~2~ is constant and, therefore, is supposed to truly reflect the real PaCO~2~ set-point ([@B2]; [@B1]; [@B36]). Recently, Weatherald et al. have pointed out that patients with resting hypocapnia (PAH, *n* = 34; CTEPH, *n* = 19; PVOD, *n* = 6) had worse cardiac function and more severe gas exchange anomalies during CPET ([@B78]). High chemosensitivity and an altered PaCO~2~ set-point were likely explanations for resting hypocapnia and high V'~E~/V'CO~2~ on exertion. The PaCO~2~ set-point, estimated by the maximal P~ET~CO~2~ was the strongest correlate of peak exercise capacity and V'~E~/V'CO~2~, suggesting that this variable could be used as a non-invasive measure of disease severity even during submaximal exercise ([@B78]). Taken together, the results of the two studies from [@B78] and [@B20] imply that hypocapnic patients and/or those with low maximal P~ET~CO~2~ during exercise have autonomic dysfunction and a lower CO~2~ set-point. Thus, resting PaCO~2~ or maximal P~ET~CO~2~ on exertion could be used to identify patients with probably autonomic dysfunction or to help develop future studies that target the sympathetic nervous system in pulmonary vascular disease.

Ventilatory limitation to exercise can also be detected in some PH patients during CPET ([Table 1](#T1){ref-type="table"}). Beside the well-known breathing reserve, i.e., the comparison of peak V'~E~ to MVV (maximal voluntary ventilation), other indicators of ventilatory limitation to exercise can be appreciated: constraints on dynamic V~T~ expansion relative to resting or dynamic decrease in inspiratory capacity (IC) used also to appreciate a critical reduction in inspiratory reserve volume (IRV) ([Table 1](#T1){ref-type="table"}; [@B38], [@B40]; [@B10]). More recently, evidence of ventilatory limitation has been suggested by the occurrence of important expiratory flow limitation (EFL) \>25% at peak exercise ([@B32]; [@B54]; [@B58]; [@B29]) and some other indicators of mechanical ventilatory limitations to exercise such as end-inspiratory lung volume (EILV) \>90% TLC alone or in combination with V~T~/IC \>70% at peak exercise have recently been observed in some patients with pulmonary vascular disease ([Table 1](#T1){ref-type="table"}). [Figure 3](#F3){ref-type="fig"} represents the typical exercise response profile of a PAH patient undergoing maximal incremental symptom-limited CPET. [Table 2](#T2){ref-type="table"} summarizes the main alterations that can be observed in patients with pulmonary vascular disease during CPET.

![Typical exercise response profile of a PAH patient (red dotted line) compared with healthy control (black line) undergoing maximal incremental symptom-limited CPET. Abbreviations in the text. This is an original figure, no permission is required.](fphys-11-00964-g003){#F3}

###### 

Typical CPET anomalies in patients with pulmonary vascular diseases.

                                                          **PAH**    **CTEPH**   **PVOD**
  ------------------------------ ------------------------ ---------- ----------- ----------
  Metabolic and cardiovascular   Peak V'O~2~              ↓          ↓           ↓
                                 V'O~2~ at AT             ↓          ↓           ↓↓
                                 V'O~2~/WR                ↓          ↓           ↓
                                 O~2~ pulse               ↓          ↓           ↓
  Ventilation and mechanics      Peak V'~E~               ↓          ↓           ↓
                                 Breathing Reserve        Normal     Normal      Normal
                                 Dynamic hyperinflation   Possible   Possible    ?
  Gas exchange                   V'~E~/V'CO~2~ slope      ↑          ↑↑          ↑↑
                                 V'~E~/V'CO~2~ at AT      ↑          ↑↑          ↑↑
                                 P~ET~CO~2~               ↓          ↓↓          ↓↓
                                 SaO~2~                   ↓          ↓↓          ↓↓
                                 P~a--ET~CO~2~            ↑          ↑↑          ↑↑
                                 P~A--a~O~2~              ↑          ↑↑          ↑↑
                                 V~D~/V~T~                ↑          ↑↑          ↑↑

CPET, cardiopulmonary exercise testing; PAH, pulmonary arterial hypertension; CTEPH, chronic thromboembolic pulmonary hypertension; PVOD; pulmonary veno-occlusive disease; V'O

2

, oxygen consumption; AT, ventilator/anaerobic threshold; WR, work rate; O

2

pulse, peak V'O

2

to heart rate ratio at peak exercise; V'E, minute ventilation; V'E/V'CO

2

, ratio of minute ventilation to carbon dioxide production (V'CO

2

); PETCO

2

, end-tidal pressure of carbon dioxide; SaO

2

, arterial oxygen saturation; PA-aO

2

, alveolar-arterial oxygen pressure gradient at peak exercise; Pa-ETCO

2

, arterial to end-tidal carbon dioxide pressure gradient at peak exercise; VD/VT, physiologic dead space fraction as ratio of dead space (VD) to tidal volume (VT) at peak exercise.

Mechanisms Explaining Exertional Dyspnea in PH {#S5}
==============================================

Exertional dyspnea is most frequent and cumbersome symptom in patients with idiopathic PAH, CTEPH, and PVOD ([@B38], [@B42], [@B40]; [@B46]; [@B10]; [Figure 4](#F4){ref-type="fig"}).

![Exertional dyspnea intensity as measured by Borg score is displayed in response to increasing work rate **(left panel)**, increasing oxygen consumption (V′~2~/Kg, **mid panel**) and increasing minute ventilation (V'~E~, **right panel**) during symptom limited cardiopulmonary exercise testing in 10 healthy subjects (black line and rhomboid), 8 patients with pulmonary veno-occlusive disease (PVOD) (violet line and circles), 16 patients with pulmonary arterial hypertension (PAH) (red line and triangles), 11 patients with chronic thromboembolic pulmonary hypertension (CTEPH) (blue line and squares). The origin of the data provided in Figure 4 is from [@B38], [@B42], [@B40]), [@B10] and [@B78].](fphys-11-00964-g004){#F4}

Although researchers have worked hard to try to explain this symptom, its underpinning mechanisms remain at present not completely understood ([@B38], [@B42], [@B40]; [@B46]; [@B10]). Previous research has particularly emphasized the cardio-and-pulmonary-vascular factors contributing to exertional dyspnea ([@B70]) by pointing out the effects of combined impaired cardiac function and abnormal pulmonary gas exchange on exertion as the result of primary anomalies of pulmonary vessels on the increased ventilatory drive and therefore on the resultant exertional dyspnea ([@B70]). Nonetheless, augmented ventilatory drive cannot alone explain the origin of the multifaceted symptom of dyspnea, and other contributions stemming from respiratory and skeletal muscle (dys)function, as well as psychological and emotional status may come into play. Recently, abnormalities of breathing mechanics have been pointed out in some PAH and CTEPH patients during exercise ([@B61]; [@B38], [@B40]; [@B15]; [@B10]; [Figure 5](#F5){ref-type="fig"}) and are likely to precipitate exertional dyspnea in these two populations ([@B38], [@B40]; [@B15]; [@B10]; [Figure 4](#F4){ref-type="fig"}).

![Tracings of lung volume (Volume) and esophageal pressure (Poes) from inspiratory capacity (IC) maneuvers taken during resting breathing, at 60 watts (iso-WR) and peak-exercise from one representative PAH patient who reduced IC (or increased end- expiratory lung volume, i.e., EELV) during exercise \[PAH hyperinflator (PAH-H), upper left panel\] and one who increased IC (or reduced EELV) \[PAH non-hyperinflator (PAH-NH), lower left panel\]. Please note that, regardless of changes in IC during exercise, dynamic peak inspiratory Poes recorded during IC maneuvers (Poes, IC) is remarkably preserved in both PAH-H (upper left panel) and PAH-NH (lower left panel). Maximal and tidal flow-volume loops (average data) are shown at rest and at peak- exercise in PAH-H (upper right panel) and PAH-NH (lower right panel). Tidal flow-volume loops are provided at rest (solid line) and at peak-exercise (dashed line). Note a significant decrease in dynamic IC during exercise in PAH-H compared with PAH-NH. TLC, total lung capacity. Reproduced with permission of [@B40].](fphys-11-00964-g005){#F5}

Now, what kind of abnormalities of breathing mechanics have been observed in PAH and CTEPH patients that can explain, at least in part, dyspnea generated during exertion and during laboratory-based CPET? Without giving to much of details on the underlying mechanisms of the anomalies of breathing mechanics encountered during CPET in PAH and CTEPH patients (which goes outside the scope of this review), we can say that some features are the development of EFL and dynamic lung hyperinflation (indicated by an increased end- expiratory lung volume, i.e., EELV that is mirrored by a decrease of the same amount/proportion in IC on exertion) with concurrent limitation of V~T~ expansion and attainment of a critical IRV in at least 60% of these patients ([@B61]; [@B38], [@B40]; [@B15]; [@B10]; [Figure 5](#F5){ref-type="fig"}). Of course some considerations must be made here: EFL is most of the time not present at rest and resting IC is preserved ([@B38], [@B40]; [@B10]), even in CTEPH pre and post-pulmonary endarterectomy ([@B60]); what is evident in 60% of these patients (PAH and CTEPH) is a reduction of the forced expiratory flow at low lung volumes (FEF~75%~) where V~T~ occurs; this predisposes to dynamic decrease in IC and limitation of V~T~ expansion with concomitant attainment of a critical IRV in some of these PAH and CTEPH patients, as it may occur in some patients with asthma ([@B41], [@B37]), chronic obstructive pulmonary disease (COPD) ([@B45], [@B43]; [@B26]; [@B68]) and chronic heart failure (CHF) ([@B44]; [@B39]; [@B67]). The sensory consequence of this is the escalation of dyspnea intensity and the transition in its qualitative description from "work/effort" to "unsatisfied inspiration" ([Figure 6](#F6){ref-type="fig"}), as is the case in some asthmatics ([@B41], [@B37]), and COPD patients ([@B45], [@B43]; [@B26]; [@B68]).

![**(A)** Selection frequency of the three descriptor phrases evaluated during symptom-limited incremental cycle exercise in patients with pulmonary hypertension (PH) who hyperinflate (Hyperinflators) during exercise: increased work/effort, unsatisfied inspiration, and chest tightness. Data are presented as mean at rest, at 20W (iso-WR 1), at 40 W (iso-WR 2), at the tidal volume (VT) inflection point, after the VT inflection point and at peak exercise. **(B)** Selection frequency of the three descriptor phrases evaluated during symptom-limited incremental cycle exercise in patients with pulmonary hypertension (PH) who deflate (Non-hyperinflators) during exercise: increased work/effort, unsatisfied inspiration, and chest tightness. Data are presented as mean at rest, at 20W (iso-WR 1), at 40 W (iso-WR 2), at the tidal volume (VT) inflection point, after the VT inflection point and at peak exercise. Reproduced with permission of [@B10].](fphys-11-00964-g006){#F6}

Of note, these particular PAH and CTEPH patients present also with a high level of anxiety which is frequently associated with dyspnea on exertion ([@B10]). It should be noted here that 40% of these PAH and CTEPH patients do not manifest decrease in IC (meaning that they deflate normally during exercise), nor limitation of V~T~ expansion nor attainment of a critical IRV during CPET ([@B38], [@B40]; [@B10]). Dyspnea intensity in this group of PAH and CTEPH is less important than in the other group previously described ([@B38], [@B40]; [@B10]) and its qualitative description remains predominantly the sense of breathing "work/effort" ([@B38], [@B40]; [@B10]; [Figure 6](#F6){ref-type="fig"}), as it occurs in healthy subjects on exertion ([@B38], [@B43]).

Another important point to bring to reader attention here is whether the dynamic decrease in IC observed during CPET in some PAH and CTEPH patients is truly reflective of dynamic lung hyperinflation or could be related to a dysfunction of inspiratory muscle (weakness or fatigue). The occurrence of fatigue or the overt presence of weakness of inspiratory muscle in PAH patients have been questioned by two studies from [@B38], [@B40]; [Figure 5](#F5){ref-type="fig"}) that have assessed the reliability of IC maneuvers in PH patients by (1) comparing inspiratory esophageal pressure (Poes) values during IC manoeuvers, (2) comparing sniff-Poes values pre- vs. post-exercise in PH patients and (3) comparing TLC pre- vs post-maximal CPET. These studies clearly pointed out that (1) Poes values measured during IC manoeuvers were remarkably preserved during exercise and were independent of exercise intensity and V'~E~ in PAH ([@B40]), (2) sniff-Poes values were identical pre- vs. post-exercise in PH patients ([@B40]) and (3) TLC pre CPET was superimposed to TLC immediately post-exercise in PH patients ([@B38], [@B40]). Taken together these findings prove that IC maneuvers are reliable ([@B38], [@B40]) and that inspiratory muscle dysfunction is unlikely to manifest, at least in these stable PAH patients ([@B38], [@B40]; [Figure 5](#F5){ref-type="fig"}).

Prognostic Utility of CPET {#S6}
==========================

There is good evidence that CPET variables can be used to measure disease severity and are predictive of survival and time to clinical worsening in PAH and CTEPH patients as well as potential treatment targets for PAH patients, with objectives of obtaining peak V'O~2~ \>15 mL.min^--1^.kg^--1^ or \> 65% predicted and a V'~E~/V'CO~2~ slope of \<36 ([@B21]; [@B58]). PAH patients with a peak V'O~2~ less than 11 mL.min^--1^.kg^--1^ or a V'~E~/V'CO~2~ slope ≥45 are considered high risk with an estimated 1-year mortality of \>10% according to European Society of Cardiology/European Respiratory Society guidelines ([@B21]). Peak V'O~2~ and V'~E~/V'CO~2~ have been associated with survival in several studies including PAH and CTEPH patients ([@B82]; [@B13]; [@B65]; [@B25]). [@B79] demonstrated that peak V'O~2~ provides additional prognostic value to resting haemodynamics in patients with PAH. Those with a low V'O~2~ (\<46.3% predicted) and PVR \>16 Wood units had a particularly dismal prognosis, while patients with peak V'O~2~ ≥ 46.3% predicted and a PVR \< 11.6 Wood units had \>90% 5-year survival. Echocardiographic assessment of RV function in combination with CPET may provide incremental prognostic utility. Badagliacca and colleagues found that RV fractional area change on echocardiogram, in conjunction with the O~2~ pulse from CPET, which reflect RV function and stroke volume, were independent predictors of outcome in patients with idiopathic PAH ([@B7]). Patients with RV fractional area change \>26.5% and an O~2~ pulse \>8.0 mL.beat^--1^ had excellent long-term survival, while PAH patients with RV fractional area change \<36.5% and an O~2~ pulse \<8.0 mL.beat^--1^ had significantly worse survival.

Others have also demonstrated that while V'~E~/V'CO~2~ slope as well as V'~E~/V'CO~2~ peak were associated with survival, once multivariate regression was performed, only ΔO~2~ pulse added prognostic value ([@B24]). Hemodynamic variables such as PVR and those that reflect right ventricular function (cardiac output, stroke volume, right atrial pressure) are also important predictors of prognosis in PAH ([@B63]; [@B75],b; [@B9]). Wensel et al. evaluated the prognostic value of combining CPET-derived variables with haemodynamic data from RHC ([@B79]) they assessed several CPET variables, including V'~E~/V'CO~2~, and found that only peak VO~2~, PVR, and HR change during exercise were independently associated with survival. Similarly, another study by Badagliacca et al., found that the only useful CPET parameter independently associated with future clinical worsening was peak VO~2~, with V'~E~/V'CO~2~ not adding additional prognostic information ([@B6]).

Conclusion {#S7}
==========

Cardiopulmonary exercise testing (CPET) is of great interest and utility for clinicians dealing with Pulmonary Hypertension (PH) in several ways such as: helping orienting diagnosis, evaluating exercise intolerance and its underpinning mechanisms, accurately assessing exertional dyspnea and unmasking its underlying often non straightforward mechanisms, generating prognostic indicators. Pathophysiologic anomalies in PH can range from reduced cardiac output and aerobic capacity, to inefficient ventilation, dyspnea, dynamic hyperinflation and locomotor muscle dysfunction. CPET can magnify the PH-related pathophysiologic anomalies and has a major role in the management of PH patients.
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